Novel anti-platelet therapy shows promise in first human trials

New anti-platelet drug set for phase II study after success in patients with coronary heart disease.

New anti-platelet drug set for phase II study after success in patients with coronary heart disease. Pictured, a blood clot in coronary artery.

Anti-platelet therapy is an important strategy for patients with coronary artery disease, who are at risk of coronary thrombosis. However, currently available therapies – such as clopidogrel – have a slow onset and are irreversible. 

Researchers report in Arteriosclerosis, Thrombosis and Vascular Biology (online, 17 December 2015[1]
) on a first-in-man study of a new anti-platelet drug called PZ-128. It has a novel mode of action, targeting the protease-activated receptor-1. 

PZ-128 was administered to participants with coronary artery disease or associated risk factors via intravenous infusion for 1-2 hours. The infusion resulted in a dose-dependent and rapid inhibition of platelet aggregation. However, this was reversible, with platelet function recovered within 24 hours of the last 0.5mg/kg dose. 

The drug will now be tested in a phase II study of patients with acute coronary syndromes, including those undergoing percutaneous coronary intervention.

 

References

[1] Gurbel PA, Bliden KP, Turner SE, et al. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arteriosclerosis Thrombosis & Vascular Biology 2016; 36: 189-197. doi: 10.1161/atvbaha.115.306777

Last updated
Citation
Clinical Pharmacist, CP, January 2016, Vol 8, No 1;8(1):DOI:10.1211/PJ.2015.20200338